L-DEP and PD-1 antibody — Competitive Intelligence Brief

L-DEP and PD-1 antibody (L-DEP and PD-1 antibody) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor combination therapy. Area: Oncology.

phase 3 PD-1 inhibitor combination therapy PD-1 Oncology Small molecule

Target snapshot

L-DEP and PD-1 antibody (L-DEP and PD-1 antibody) — Beijing Friendship Hospital. L-DEP and PD-1 antibody is a combination therapy that enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while L-DEP provides immunomodulatory support.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-DEP and PD-1 antibody TARGET	L-DEP and PD-1 antibody	Beijing Friendship Hospital	phase 3	PD-1 inhibitor combination therapy	PD-1
Penpulimab kcqx	PENPULIMAB	Akeso Biopharma	marketed		Pd-1	2025-01-01
Tevimbra	TISLELIZUMAB	Beigene	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2025-01-01
Loqtorzi	TORIPALIMAB	Coherus Biosciences Inc	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2024-01-01
Unloxcyt	COSIBELIMAB	Checkpoint Therapeutics Inc	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	2024-01-01
Jemperli	DOSTARLIMAB	GSK	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	PD-1	2021-01-01
Libtayo	CEMIPLIMAB	Regeneron Pharmaceuticals	marketed		PD-1	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor combination therapy class)

1. Beijing Friendship Hospital · 1 drug in this class